How Immune Cells Facilitate the Spread of Breast Cancer
News Apr 02, 2015
The body's immune system fights disease, infections and even cancer, acting like foot soldiers to protect against invaders and dissenters. But it turns out the immune system has traitors amongst their ranks.
Dr. Karin de Visser and her team at the Netherlands Cancer Institute discovered that certain immune cells are persuaded by breast tumors to facilitate the spread of cancer cells.
In Western countries about one in eight women will develop breast cancer. Of the women who die of this disease, 90 percent dies because the cancer has spread to other parts of their body and formed metastases. For this reason, cancer researchers are trying to understand how the process of metastasis occurs.
A few years ago, it was reported that breast cancer patients with a high number of immune cells called neutrophils in their blood are at increased risk of developing metastases. Immune cells are supposed to protect our body. So why are high neutrophil levels linked to worse outcome in women with breast cancer?
Dr. Karin de Visser, group leader at the Netherlands Cancer Institute, and her team discovered that certain types of breast tumors cause a domino effect of reactions within the immune system. The tumor sends out signaling molecules that through a number of steps cause the immune system to produce lots of neutrophils. This normally happens as part of an inflammatory reaction, but the neutrophils that are activated by the tumor behave differently. It turns out they are able to block the actions of other immune cells, called T cells. T cells are the cells that can (sometimes) recognize and kill cancer cells.
De Visser and her team went on to discover that a signaling protein called interleukin 17 (or IL17) is important for this process. "We saw in our experiments that IL17 is crucial for the increased production of neutrophils", says De Visser. "And not only that, it turns out that this is also the molecule that changes the behavior of the neutrophils, causing them to become T cell inhibitory."
The first author of the study, postdoctoral researcher Seth Coffelt, showed the importance of the IL17-neutrophil pathway by inhibiting this pathway in a mouse model that mimics human breast cancer metastasis. When neutrophils were inhibited, the animals developed much less metastases than animals from the control group, in which the IL17-neutrophil route was not inhibited. "What's notable is that blocking the IL17-neutrophil route prevented the development of metastases, but did not affect the primary tumor," De Visser comments. "So this could be a promising strategy to prevent the tumor from spreading."
Since neutrophils are important to protect us from infections, drugs that inhibit neutrophils would make patients susceptible to all kinds of infections. Inhibition of IL17 might be a safer strategy. In fact, drugs that do so already exist. Anti-IL17 drugs are currently being tested in clinical trials as a treatment for inflammatory diseases, like psoriasis and rheumatism. Last month, the first anti-IL17 based therapy for psoriasis patients was approved by the U.S. Federal Drug Administration (FDA). "It would be very interesting to investigate whether these already existing drugs are beneficial for breast cancer patients. It may be possible to turn these traitors of the immune system back towards the good side and prevent their ability to promote breast cancer metastasis," De Visser says.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Lissencephaly Modeled in a Dish for the First TimeNews
Researchers describe how cells from patients with the severe developmental disease lissencephaly differ from healthy cells. The method can provide vital new knowledge on difficult-to-study congenital diseases.READ MORE
Comments | 0 ADD COMMENT
9th International conference on Tissue Engineering and Regenerative Medicine
Nov 09 - Nov 10, 2018